Involvement of angiotensin II, TRH and prolactin-releasing peptide in the estrogen-induced afternoon prolactin surge in female rats: studies using antisense technology.
The roles of endogenous angiotensin II (AII), thyrotropin-releasing hormone (TRH) and prolactin-releasing peptide (PrRP) on the estrogen-induced prolactin (PRL) surge and the diurnal change of tuberoinfundibular dopaminergic (TIDA) neuronal activity were assessed in this study. Ovariectomized, estrogen-primed rats implanted with intracerebroventricular cannula received daily injection of antisense oligodeoxynucleotide (ODN, 10 microg/3 microl) against the mRNA of AII, TRH or PrRP for two days. Artificial cerebrospinal fluid or the sense ODN were used as the control. In the first experiment, serial blood samples (0.3 ml each) were obtained hourly from each rat through a pre-implanted intraatrial catheter from 1100 to 1700h. Half of the rats pretreated with respective antisense ODN received single injections of AII, TRH or PrRP (1 microg each, i.v.) at 1400h. In the second experiment, groups of rats were decapitated either at 1000 or 1500h. The hypothalamic median eminence tissue of each rat was dissected out and its DOPAC content was used as the index for TIDA neuronal activity. Plasma and serum PRL levels were determined by radioimmunoassay. Pretreatment of antisense ODN against the mRNA of either AII or TRH significantly attenuated the PRL surge; replacement injection of AII or TRH restored the surge. The effect of antisense ODN against PrRP was less significant. None of the treatments significantly affected the diurnal changes of TIDA neuronal activity. In summary, both AII and TRH may play an important role as the PRL-releasing hormone involved in the estrogen-induced afternoon PRL surge.
Yuan
Zung Fan
ZF
Department of Physiology, School of Life Science, National Yang-Ming University, 11221, Taipei, Taiwan
Pan
Jenn-Tser
JT
D000804:Angiotensin II / Q000494:pharmacology*; D000818:Animals; D002940:Circadian Rhythm / Q000187:drug effects; D004298:Dopamine / Q000502:physiology; D004967:Estrogens / Q000494:pharmacology*; D005260:Female; D007028:Hypothalamic Hormones / Q000502:physiology*; D007276:Injections, Intraventricular; D009479:Neuropeptides / Q000502:physiology*; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage / Q000494:pharmacology*; D010052:Ovariectomy; D011388:Prolactin / Q000097:blood*; D056690:Prolactin-Releasing Hormone; D051381:Rats; D013973:Thyrotropin-Releasing Hormone / Q000037:antagonists & inhibitors / Q000494:pharmacology*
D004967:Estrogens; D007028:Hypothalamic Hormones; D009479:Neuropeptides; D016376:Oligonucleotides, Antisense; C534379:Prlh protein, rat; D056690:Prolactin-Releasing Hormone; D000804:Angiotensin II; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin; D004298:Dopamine